Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 96,500 shares, an increase of 59.2% from the January 31st total of 60,600 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average daily volume of 813,300 shares, the short-interest ratio is presently 0.1 days.

Adial Pharmaceuticals Trading Up 1.9 %

ADIL stock opened at $0.79 on Friday. The business’s 50 day moving average price is $0.91 and its two-hundred day moving average price is $0.99. Adial Pharmaceuticals has a fifty-two week low of $0.72 and a fifty-two week high of $3.60.

Institutional Trading of Adial Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new stake in shares of Adial Pharmaceuticals in the fourth quarter worth about $48,000. Citadel Advisors LLC increased its stake in Adial Pharmaceuticals by 63.8% in the 4th quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock worth $55,000 after acquiring an additional 21,238 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Adial Pharmaceuticals by 36.0% during the 4th quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock worth $62,000 after acquiring an additional 16,381 shares in the last quarter. Hedge funds and other institutional investors own 16.41% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on ADIL. Rodman & Renshaw began coverage on Adial Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $8.00 price objective for the company. RODMAN&RENSHAW raised shares of Adial Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.